Jeff Jones, DVM, PhD Animal Biotechnology Interdisciplinary Group Center for Veterinary Medicine U.S. Food and Drug Administration Regulation of Genetically.

Slides:



Advertisements
Similar presentations
Biopharmaceutical Quality
Advertisements

Office of New Animal Drug Evaluation Laura L. Hungerford, DVM, MPH, PhD Senior Advisor, Science and Policy, ONADE Professor, University of Maryland School.
Regulatory Clinical Trials Clinical Trials. Clinical Trials Definition: research studies to find ways to improve health Definition: research studies to.
Effectiveness Evaluation for Production Drugs Crystal Groesbeck, Ph.D Division of Production Drugs.
Safety Guidelines Illness and Injury Prevention Safety Guidelines Illness and Injury Prevention 2.01 Understand safety procedures 1.
Phenotypic Characterization Harlan Howard, PhD. Describes the animal, construct, and proposed claim Are there sequences that are likely to contain potential.
Eric Schulze, PhD Animal Biotechnology Interdisciplinary Group Center for Veterinary Medicine U.S. Food and Drug Administration Regulation of Animal Biotechnology.
1 MANUFACTURING AND PRODUCTION OF BIOLOGICAL PRODUCTS (ERT 455) HAZARD ANALYSIS AND CRITICAL CONTROL POINT (HACCP) SYSTEM Munira Mohamed Nazari School.
Current Perspectives on Biotechnology: Projects and Future Challenges/Opportunities Jordan BeanDr. Jaimie Schnell Novel Foods SectionPlant Health and Biotechnology.
Molecular Biology. It’s a Matter of Perspective The investigators who submit IBC protocols want to perform their experiments safely. The investigators.
Regulation and Safety Assessment of Novel Foods in Canada William Yan, Ph.D. Office of Food Biotechnology Health Canada.
1 Performance Modifiers. 2 The Problem After the realization that animals had a need for protein supplementation the livestock industry was still trying.
What Do Toxicologists Do?
Safety and Regulation in Agricultural Biotechnology MUPGRET Workshop.
Food Safety Assessment Kevin Greenlees, PhD, DABT Kathleen Jones, PhD.
Effectiveness Evaluation for Therapeutic Drugs for Non-Food Animals
Environmental Safety Assessment Eric Silberhorn, PhD, DABT.
FDA’s Policy for Evaluating Bioengineered Foods Jeanette Glover Glew Food and Drug Administration Center For Food Safety and Applied Nutrition September,
Background, Introduction, Statutory Authority, Introduction to Risk-Based Approach Larisa Rudenko, PhD, DABT.
INADs and Beginning the Review Process Larisa Rudenko, PhD, DABT.
Animal Feed GRAS Notifications Geoffrey K. Wong, M.S. Division of Animal Feeds Center for Veterinary Medicine Pet Food Institute Pet Food Institute October.
Malini M. Wileman, PhD, RAC Animal Biotechnology Interdisciplinary Group Center for Veterinary Medicine U.S. Food and Drug Administration Regulation of.
Mrs. Brandi Robinson Office of New Animal Drug Evaluation Center for Veterinary Medicine Regulating Animal Drugs.
Durability Joseph W. (Jay) Cormier, PhD. Describes the animal, construct, and proposed claim Are there sequences that are likely to contain potential.
Codex Guidelines for the Application of HACCP
Great Plains Veterinary Educational Center A Little On Drug Use Antibiotic Use GuidelinesAMDUCA (Animal Medicinal Drug Use Clarification Act)ELDU (Extra.
AquaAdvantage Salmon Lisa Danielson. Outline Introduction Explanations Significance Research Question Methodology My approach Literature Review Problems.
Good Laboratory Practices (GLPs)
Good Laboratory Practice
Center for Veterinary Medicine (CVM) RECALLS.  21 CFR 7.40 provides guidance on the policy, procedures, and industry responsibilities for recalls. 
Nonclinical Studies Subcommittee Advisory Committee for Pharmaceutical Science CMC Issues for Screening INDs Eric B. Sheinin, Ph.D. Acting Deputy Director.
Physiologists & the FDA Kevin J. Greenlees, Ph.D., DABT Senior Advisor for Science & Policy Office of New Animal Drug Evaluation FDA Center for Veterinary.
FDA/CFSAN’s Science-based Approach to the Safety of Foods Derived from Modern Biotechnology Thomas A. Cebula, Ph.D. Director, Office of Applied Research.
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
INTRODUCTION TO TOXICOLOGY SIDNEY GREEN, PH.D. DEPARTMENT OF PHARMACOLOGY COLLEGE OF MEDICINE HOWARD UNIVERISTY.
Safety organization and training. The biosafety officer and biosafety committee A safety policy, A safety manual, and Supporting programmes for their.
Presenter’s Name June 17, Directions for this Template  Use the Slide Master to make universal changes to the presentation, including inserting.
Final Rule for Preventive Controls for Human Food September 16, THE FUTURE IS NOW 1.
Proposed Rule for Preventive Controls for Animal Food.
Proposed Rule: 21 CFR 507 Proposed Rule for Preventive Controls for Animal Food 1.
Center for Drug Evaluation and Research (CDER) Tanya Eberle Kamal Diar David Clements.
Codex Science-based Approach to the Safety of Foods Derived from Modern Biotechnology James H. Maryanski, Ph.D. Food and Drug Administration Center for.
Substantial Evidence of Drug Effectiveness Cindy L. Burnsteel, DVM Division of Therapeutic Drugs for Food Animals Center for Veterinary Medicine March.
COMPARABILITY PROTOCOLUPDATE ADVISORY COMMITTEE FOR PHARMACEUTICAL SCIENCE Manufacturing Subcommittee July 20-21, 2004 Stephen Moore, Ph.D. Chemistry Team.
Biotechnology. D Biotechnology2 Definition Techniques used to modify deoxyribonucleic acid (DNA) or the genetic material of a microorganism, plant,
Environmental Assessment of Genetically Engineered Animals at CVM (FDA) Animal Biotechnology Interdisciplinary Group Center for Veterinary Medicine U.S.
Nanotechnology - USDA - 18 Nov 2002 REGULATORY CONSIDERATIONS FOR NANOTECHNOLOGY IN PUBLIC HEALTH FOOD AND DRUG ADMINISTRATION Norris E. Alderson, Ph.D.
Final Rule for Preventive Controls for Animal Food 1 THE FUTURE IS NOW.
Environmental Assessment of Genetically Engineered Animals at CVM (FDA) Animal Biotechnology Interdisciplinary Group Center for Veterinary Medicine U.S.
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
Awareness Training: ‘HARPC’ for Food Safety Complimentary Presentation by Quality Systems Enhancement 1790 Wood Stock Road Roswell GA E. mail:
Evaluating the Safety of Antimicrobial New Animal Drugs with Regard to Their Microbiological Effects on Bacteria of Human Health Concern Qualitative Antimicrobial.
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
DEPARTMENT OF HEALTH CENTER FOR BIOLOGICS AND HUMAN SERVICESEVALUATION and RESEARCH AND HUMAN SERVICES EVALUATION and RESEARCH Update on OCTGT Guidance.
FAS Training 2016 SMR 4 Food and Feed Hygiene Carrick on Shannon, Charleville, Kilkenny Integrated Controls Division 1.
Regulation of Generic Animal Drugs in the United States
In the name of God. Common Technical Document On Biotech.
It’s a food… It’s a drug… It’s AquAdvantage Salmon! Ricardo Carvajal Hyman, Phelps & McNamara, P.C st Annual Tulane.
BIOTECHNOLOGY A Review. What is biotechnology? Any technological application that uses biological systems, living organisms or derivatives thereof, to.
Regulatory Agencies What are regulatory issues? Types of agencies How they affect you Top 10 regulatory issues.
Emily Marden Sidley Austin LLP University of British Columbia
Final Rule for Preventive Controls for Human Food
HACCP Essential Tool for Food Safety
Safety Guidelines Illness and Injury Prevention
From Lab to Label: Innovations That Feed The World
Safety Guidelines Illness and Injury Prevention
Regulatory Perspective of the Use of EHRs in RCTs
Safety Guidelines Illness and Injury Prevention
FDA Regulation of Animal Biotechnology Products
VICH GL 54, Studies to evaluate the safety of residues of veterinary drugs in human food: General approach to establish an Acute Reference Dose (ARfD)
Presentation transcript:

Jeff Jones, DVM, PhD Animal Biotechnology Interdisciplinary Group Center for Veterinary Medicine U.S. Food and Drug Administration Regulation of Genetically Engineered Animals at FDA: A Case Study

Our First Approval: GE Goats Producing Human Antithrombin

Considerations –Two regulated articles –Characteristics and intended use of second article determine that review Goals –Risk-based, non-duplicative reviews –Coordinated with “Final Product” Center –Harmonized data/review requirements GE Animals for Biopharmaceutical Production

Our First Approval: GE Goats Producing Human Antithrombin

No hazards identified Under GTC Management/procedures –Safe to the animal –Food/Feed Safety addressed (not for food) –Safe for the environment Effective –rhAT in the milk Overarching Conclusions

Hierarchical Risk-Based Evaluation (by level)

Broad statement identifying GE animal and claim A specific hemizygous diploid line of domestic goats (Capra aegagrus hircus) containing 5 copies of the Bc6 construct located at the GTC site, directing the expression of the human gene for antithrombin (which is intended for the treatment of humans) in the mammary gland of goats derived from Founder Product Definition

Data/Information Reviewed –Source and description of rDNA intended for GE animal –Construction, including method and intermediate organisms –Sequence of the final product –Potential contaminants in the injection solution Conclusions –Data adequate to support the Molecular Characterization of the Construct –No hazards intrinsically present in the construct; no hazardous contaminants What is the construct? How is/was it made? Molecular Characterization of the Construct

Data/Information Reviewed –Characterization of construct in the animal –Stability over multiple generations –Expression of the rDNA construct in the animal –Characterization of the expression product Conclusions –Data adequate to support the Molecular Characterization of the GE Animal Lineage –No hazards posed by the presence of this rDNA –rDNA construct stable over multiple generations What was the result of integration? (including stable inheritance?) Molecular Characterization of the GE Animal Lineage

Health, Husbandry Data/Information Reviewed –Animal breeds, sources –Husbandry methods (e.g., animal identification, housing, feed) –Health management (e.g., health evaluations, preventative procedures, biosecurity measures, health observations) –Animal performance (e.g., growth, reproduction, feed consumption) –Milk production and composition –Production of rhAT in milk Safe for the animal? Does it still function as a goat? Effect of introduction of rDNA construct? Phenotypic Characterization

Conclusions –Animals housed in high quality conditions; biosecure; highly contained –General health, growth, milk production, and reproduction of multiple generations the line of goats comparable to non-GE herd-mates and/or historical comparators –Milk composition of the line of goats is comparable to non-GE herd-mates or historical comparators (except for the presence of rhAT) Phenotypic Characterization (2)

Information Reviewed –Sponsor-developed plan including: Testing frequency, Validated test methods, Test specifications and reporting schedule, Lineage replacement and out-of-specification procedures Conclusion –Submitted plan expected to ensure future consistency of the approved GE animal lineage Future GE animals equivalent to approved animals? Genotypic and Phenotypic Durability Plan

Information Reviewed –Sponsor affirmation –Animal ID; facilities; containment procedures –Animal/product disposition methods and records –“Regulatory Method” for rDNA identification Conclusions –Plan submitted expected to ensure that materials from this GE animal lineage will not enter food/feed –Regulatory method available if needed Approval specifically prohibits the use of these animals for food or feed Food/Feed Safety

Data/Information Reviewed –Gene construct, GE animal, goat farm (previous steps of review process); containment, handling/disposal of wastes & carcasses –Two site visits; focus on animal health/containment Conclusions –No environmental risks associated with confined rhAT goats, waste products –Multiple levels of containment make escape unlikely In event of escape without recapture, survival, reproduction, and population establishment in the surrounding environment is highly unlikely Environmental risks while under confinement? Likelihood of escape? Potential adverse outcomes associated with escape? Environmental Safety

Data/Information Reviewed: –Materials and conclusions of the previous steps –Molecular identification of expression product Conclusion – lineage produces rhAT in milk –Data support the product definition for the line of goats GE animal does what the product definition claims? Claim Validation

Characterization of rDNA construct/lineage acceptable Insertion is stable; adequate plan to ensure that future animals are equivalent to those evaluated for safety and effectiveness No identified risks to GE animals or the environment Affirmation of exclusion from food/feed Acceptable controls and procedures by sponsor Regulatory method available rDNA construct effectively produces rhAT Overall Conclusions (NADA)

Contact Information

CBER: US FDA Center for Biologics Evaluation and Research CVM: US FDA Center for Veterinary Medicine GE: Genetically Engineered GFI: Guidance for Industry ID: Identification NADA: New Animal Drug Application rDNA: Recombinant Deoxyribonucleic Acid rhAT: Recombinant Human Antithrombin US FDA: United States Food and Drug Administration Acronyms